BG
BIO icon

BlackRock Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

BlackRock Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$5M Buy
27,459
+1,412
+5% +$241K ﹤0.01% 1193
2016
Q3 		$4.27M Sell
26,047
-627
-2% -$95.2K ﹤0.01% 1182
2016
Q2 		$3.82M Sell
26,674
-55,344
-67% -$7.89M ﹤0.01% 1206
2016
Q1 		$11.2M Buy
82,018
+3,180
+4% +$417K 0.01% 898
2015
Q4 		$10.9M Sell
78,838
-4,705
-6% -$652K 0.01% 904
2015
Q3 		$11.2M Buy
83,543
+31,183
+60% +$4.49M 0.01% 894
2015
Q2 		$7.88M Buy
52,360
+32,762
+167% +$4.69M ﹤0.01% 1024
2015
Q1 		$2.65M Sell
19,598
-703
-3% -$87.1K ﹤0.01% 1356
2014
Q4 		$2.45M Buy
20,301
+3,123
+18% +$359K ﹤0.01% 1393
2014
Q3 		$1.95M Buy
17,178
+3,617
+27% +$429K ﹤0.01% 1431
2014
Q2 		$1.62M Sell
13,561
-1,202
-8% -$147K ﹤0.01% 1570
2014
Q1 		$1.89M Buy
14,763
+4,079
+38% +$523K ﹤0.01% 1606
2013
Q4 		$1.32M Sell
10,684
-935
-8% -$114K ﹤0.01% 1806
2013
Q3 		$1.37M Buy
11,619
+880
+8% +$104K ﹤0.01% 1712
2013
Q2 		$1.21M Buy
+10,739
New +$1.26M ﹤0.01% 1616

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

BlackRock Group's BIO Position: Q4 2016 in Review

BlackRock Group increased its Bio-Rad Laboratories Class A (BIO) stake by 5.4% in Q4 2016, buying an estimated $241K and bringing the position to 27,459 shares worth $5M. The position accounts for ﹤0.01% of the portfolio, ranked #1193.

BlackRock Group first reported a position in BIO in Q2 2013 and has held it in 15 quarters since. The position peaked at $11.2M in Q3 2015. 261 funds tracked by Wall St. Rank hold BIO as of Q4 2016.

  • BlackRock Group held 27,459 shares of Bio-Rad Laboratories Class A worth $5M as of Q4 2016.
  • BlackRock Group bought 1,412 Bio-Rad Laboratories Class A shares in Q4 2016, an estimated $241K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1193 holding.
  • BlackRock Group first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Bio-Rad Laboratories Class A position peaked at $11.2M in Q3 2015.
  • 261 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.